Follow-up studies found TP-0903 to be highly effective in preclinical models of TP53-mutated AML; TP-0903 was found to be more effective than decitabine and to have additive activity with decitabine in vitro and in vivo. The gene discussed is TP53; the disease is acute myeloid leukemia.